Abstract
Alternative strategies exist for prevention of group B Neisseria meningitidis (meningococcal) disease through vaccination (see Chapters 5, 8, 13, 14 in this volume). However, the most promising approach to date has been the use of outer-membrane vesicle (OMV) vaccines for induction of bactericidal antibodies against cell-surface outer-membrane proteins (OMPs).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Zollinger, W. D. (1997) New and improved vaccines against meningococcal disease, in New Generation Vaccines, 2nd ed. (Levine, M. M., Woodrow, G. C., Kaper, J. B., and Cobon, G. S., eds.), Marcel Dekker, New York, 469–488.
Bjune, G., Hoiby, E. A., Gronnesby, J. K., Arnesen, O., Fredriksen, J. H., Halstensen, A., et al. (1991) Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338, 1093–1096.
Sierra, G. V. G., Campa, H. C., Varcacel, N. M., Izquierdo, P. L., Sotolongo, P. F., Casanueva, G. V., et al. (1991) Vaccine against group B Neisseria meningitidis: Protection trial andmass vaccination results in Cuba. NIPH. Ann. 14, 195–210.
Perkins, B. A., Jonsdottir, K., Briem, H., Griffiths, E., Plikaytis, B. D., Høiby, E. A., et al. (1998) Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis. 177, 683-669.
Tappero, J. W., Lagos, R., Ballesteros, A. M., Plikaytis B., Williams D., Dykes J., et al. (1999) Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines. A randomized controlled trial in Chile. JAMA 281, 1520–1527.
Milagres, L. G., Ramos, S. R., Sacchi, C. T., Melles, C. E. A., Vieira, V. S. D., Sato, H., et al. (1994) Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: Comparison with efficacy. Infect. Immun. 62, 4419–4424.
Frasch, C. E. (1995) Meningococcal vaccines: past present and future, in Meningococcal Disease (Cartwright, K. A. V., ed.), John Wiley and Sons, New York, pp. 245–283.
Peltola, H. (1998) Meningococcal vaccines: current status and future possibilities. Drugs 55, 347–366.
Van der Voort, E. M. R., Kuipers, B., Brugghe, H. F., Van Unen, L. M. A., Timmermans, H. A. M., Hoogerhout, P., and Poolman, J. T. (1997) Epitope specificity of murine and human bactericidal antibodies against PorA P1.7,16 induced with experimental meningococcal group B vaccines. FEMS Immunol. Med. Microbiol. 17, 139–148.
Wang, J. F., Jarvis, G. A., Achtman, M., Rosenqvist, E., Michaelsen, T. E., Aase, A., and Griffiss, J. M. (2000) Functional activities and immunoglobulin variable regions of human and murine monoclonal antibodies specific for the P1.7 PorA protein loop of Neisseria meningitides. Infect. Immun. 68, 1871–1878.
Barlow, A. K., Heckels, J. E., and Clarke, I. N. (1989) The class I outer membrane protein of Neisseria meningitidis: Gene sequence, structural and immunological similarities to gonococcal porins. Mol. Microbiol. 3, 131–139.
Minetti, C., Song, J., and Blake, M.S. (1998) Meningococcal PorA class 1 proteins exist in nature as a heterotrimeric proin with porB proteins, in Eleventh International Pathogenic Neisseria Conference (Nassif, X., Quentin-Millet, M-J., and Taha, M-K., eds.), EDK, Paris, p. 15.
Jones, D. M., Borrow, R., Fox, A. J., Gray, S., Cartwright, K. A., and Poolman, J. T. (1992) The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis. Microb. Pathog. 13, 219–224.
Zollinger, W. D., Moran, E. E., Devi, S. J. N., and Frasch, C. E. (1997) Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. Infect. Immun. 65, 1053–1060.
Sacchi, C. T. (1998) Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature. Clin. Diagn. Lab. Immunol. 5, 845–855.
Wetzler, L. M., Blake, M. S., Barry, K., and Gotschlich, E. C. (1992) Gonococcal porin vaccine evaluation: comparison of Por proteosomes, liposomes, and blebs isolated from rmp deletion mutants. J. Infect. Dis. 166, 551–555.
Steeghs, L., Kuipers, B., Hamstra, H. J., Kersten, G., Van Alphen, L., and Van der Ley, P. (1999) Immunogenicity of outer membrane proteins in a lipopolysaccharide-deficient mutant of Neisseria meningitidis: influence of adjuvants on the immune response. Infect. Immun. 67, 4988–4993.
Helting, T. B., Guthohrlein, G., Blackkolb, F., and Ronneberger, H. (1981) Serotype determinant protein of Neisseria Meningitidis. Large scale preparation by direct detergent treatment of the bacterial cells. Acta Pathol. Microbiol. Scand. [C] 89, 69–78.
Frasch, C. E. (1990) Production and control of Neisseria meningitidis vaccines, in Bacterial Vaccines (Mizrahi, A., ed.), Wiley-Liss, New York, pp. 123–145.
Poolman, J. T. (1990) Polysaccharides and membrane vaccines, in Bacterial Vaccines (Mizrahi, A., ed.), Wiley-Liss, New York, pp. 58–86.
Holst Fredriksen, J., Rosenqvist, E., Wedege, E., Bryn, K., Bjune, G., Frøholm, L. O., et al. (1991). Production characterization and control of MenB-vaccine “Folkehelsa”: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 14, 67–80.
Fu, J., Bailey, F. J., King, J. J., Parker, C. B., Robinett, R. S. R., Kolodin, D. G., et al. (1995) Recent advances in the large scale fermentation of Neisseria meningitidis group B for the production of an outer membrane protein complex. BioTechnology 13, 170–174.
Brandileone, M. C., Zanella, R. C., Vieira, V. S., Sacchi, C. T., Milagres, L. C., and Frasch, C. E. (1994) Induction of iron regulated proteins during normal growth of Neisseria meningitidis in a chemically defined medium. Rev. Inst. Med. Trop. Sao Paulo 36, 301–310.
Tsai, C. M., Frasch, C. E., Rivera, E., and Hochstein, H. D. (1989) Measurement of lipopolysaccharide (endotoxin) in meningococcal protein and polysaccharide preparations for vaccine usage. J. Biol. Stand. 17, 249–258.
Rosenqvist, E., Hoiby, E. A., Bjune, G., Aase, A., Halstensen, A., Lehmann, A. K., et al. (1998) Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine. Dev. Biol. Stand. 92, 323–333.
Frasch, C. E., Peppler, M. S., Cate, T. R., and Zahradnik, J. M. (1982) Immunogenicity and clinical evaluation of group B Neisseria meningitidis outer membrane protein vaccines. IN: Robbins, J. B., Hill, J. C., and Sadoff, J. C. (eds.), Sem. Infect. Dis. 4, 263–267, Thieme-Stratton, NY, NY.
Frantz, I. D. (1942) Growth requirements of the meningococcus. J. Bacteriol. 43, 757–761.
Frasch, C. E., McNelis, R. M., and Gotschlich, E. C. (1976) Strain-specific variation in the protein and lipopolysaccharide composition of the group B meningococcal outer membrane. J. Bacteriol. 127, 973–981.
Van der Ley, P. A. and Poolman, J. (1992) Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect. Immun. 60, 3156–3161.
Van der Ley, P. A., van der Biezen, J., and Poolman, J. T. (1995) Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane protein vaccine. Vaccine 13, 401–407.
Tommassen, J., Vermeij, P., Struyvé, M., Benz, R., and Poolman, J. T. (1990) Isolation of Neisseria meningitidis mutants deficient in class I (Pora) and class 3 (PorB) outer membrane proteins. Infect. Immun. 58, 1355–1359.
Frosch, M., Schultz, E., Glenn-Clavo, E., and Meyer, T. F. (1990) Generation of capsule-deficient Neisseria meningitidis strains by homologous recombination. Mol. Microbiol. 4, 1215–1218.
Rosenqvist, E., Hoiby, E. A., Wedege, E., Kusecek, B., and Achtman, M. (1993) The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J. Infect. Dis. 167, 1065–1073.
Banerjee-Bhatnager, N. and Frasch, C. E. (1990). Expression of ironregulated outer membrane proteins in Neissera meningitidis including a 70-kDa transferrin receptor and the vaccine potential of these proteins. Infect. Immun. 58, 2875–2881.
Frasch, C. E., Zahradnik, J. M., Wang, L. Y., Mocca, L. F., and Tsai, C. M. (1988) Antibody response of adults to an aluminum hydroxide-adsorbed Neisseria meningitidis serotype 2b protein-group B polysaccharide vaccine. J. Infect. Dis. 158, 710–718.
Hem, S. L. and White, J. L. (1984) Characterization of aluminum hydroxide for use as an adjuvant in parenteral vaccines. J. Parenter. Sci. Technol. 38, 2–10.
Burrell, L. S., Lindblad, E. B., White, J. L., and Hem, S. L. (1999) Stability of aluminium-containing adjuvants to autoclaving. Vaccine 17, 2599–2603.
MacDonald, N. E., Halperin, S. A., Law, B. J., Forrest, B., Danzig, L. E., and Granoff, D. M. (1998) Induction of immunologic memory by conjugated versus plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 280, 1685–1689.
Lieberman, J. M., Chiu, S. S., Wong, V. K., Partridge, S., Chang, S. J., Chiu, C. Y., et al. (1996) Safety and immunogenicity of a serogroups A/C Neisseria meningitides oligosaccharide-protein conjugate vaccine in young children: a randomized controlled trial. J. Amer. Med. Assoc. 275, 1499–1503.
Fukasawa, L. O., Gorla, M. C. O., Schenkman, R. P. F., Garcia, L. R., Carneiro, S. M., Rawa, I., and Tanizaki, M. M. (1999) Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate. Vaccine 17, 2951–2958.
Holst Fredriksen, J., Griffiths, E., Grotterød, E. M., Høiby, E. A., Rosenqvist, E., Stevenson, P., and Wedege, E. (1994) Characterization of high molecular weight components in MenB-vaccine “Folkehelsa”; An outer membrane vesicle vaccine against group B meningococcal disease, in Pathobiology and Immunobiology of Neisseriaceae (Conde-Glez, C. J., Morse, S., Rice, P., Sparling, F., and Calderôn, E. eds.), Instituto National de Salud Publica, Cuernovaso, Mexico, pp. 818–824.
Griffiths, E., Sierra, G., and Holst, J. (1994) Quality control of the Cuban and Norwegian serogroup B vaccines used in the Iceland study, in Proceedings of the Ninth International Pathogenic Neisseria Conference (Evans, J. S., Yost, S. E., Maiden, M. C. J., and Feavers, I. M., eds.), Winchester, UK, p. 437.
Claassen, I., Meylis, J., van der Ley, P., Peeters, C., Brons, H., Robert, J., et al. (1996) Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14, 1001–1008.
Wenger, J. D. (1999) Serogroup B meningococcal disease. New outbreaks, new strategies. JAMA 281, 1541–1543.
Peterson, G. L. (1977) A simplification of the protein assay of Lowry et al. which is more generally applicable. Anal. Biochem. 83, 346–356.
Lee, C-H. and Tsai, C-M. (1999) Quantification of bacterial lipopolysaccharide by the Purpald assay: measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation. Anal. Biochem. 267, 161–168.
Tsai, C-M., Frasch, C. E., Rivera, E., and Hochstein, H. D. (1989) Measurement of lipopolysaccharide (endotoxin) in meningococcal protein and polysaccharide preparations for vaccine usage. J. Biol. Stand. 17, 229–258.
Brunborg, G., Holme, J. A., Søderlund, E. G., Omichinski, J. G., and Dybing, E. (1988) An automated alkaline elution system: DNA damage induced by 1,2-dibromo-3-chloropropane in vivo and in vitro. Anal. Biochem. 174, 522–536.
Clarke, A. J., Sarabia, V., Keenleyside, W., MacLachlan, P. R., and Whitfield, C. (1991) The compositional analysis of bacterial extracellular polysaccharides by high-performance anion-exchange chromatography. Anal. Biochem. 199, 68–74.
Abdillahi, A. and Poolman, J. T. (1988) Neisseria meningitidis group B serosubtyping using monoclonal antibodies in whole cell ELISA. Microbiol. Pathog. 4, 27–32.
Shrivastaw, K. P. and Singh, S. (1995) A new method for spectrophotometric determination of thiomersal in biologicals. Biologicals 23, 65–69.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Frasch, C.E., van Alphen, L., Holst, J., Poolman, J.T., Rosenqvist, E. (2001). Outer Membrane Protein Vesicle Vaccines for Meningococcal Disease. In: Pollard, A.J., Maiden, M.C. (eds) Meningococcal Vaccines. Methods in Molecular Medicine™, vol 66. Humana Press. https://doi.org/10.1385/1-59259-148-5:81
Download citation
DOI: https://doi.org/10.1385/1-59259-148-5:81
Publisher Name: Humana Press
Print ISBN: 978-0-89603-801-1
Online ISBN: 978-1-59259-148-0
eBook Packages: Springer Protocols